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Abstract
Although aluminum excess is an apparent pathogenetic factor
underlying osteomalacia in dialysis-treated patients with chronic
renal failure, the mechanism by which aluminum impairs bone
mineralization is unclear. However, the observation that alu-
minum is present at osteoid-bone interfaces in bone biopsies
of affected patients suggests that its presence at calcification
fronts disturbs the cellular and/or physiochemical processes
underlying normal mineralization. Alternatively, aluminum at
osteoid-bone interfaces may reflect deposition in preexistent
osteomalacic bone without direct effects on the mineralization
process. We investigated whether aluminum accumulates pref-
erentially in osteomalacic bone and, if so, whether deposition
of aluminum occurs at calcification fronts and specifically
inhibits mineralization.
Aluminum chloride (1 mg/kg) was administered intrave-
nously three times per week for 3 wk to five normal and five
vitamin D-deficient osteomalacic dogs. Before administration
of aluminum the vitamin D-deficient dogs had biochemical and
bone biopsy evidence of osteomalacia. Bone aluminum content
in the osteomalacic dogs (15.1±2.2 gg/g) and the plasma
aluminum concentration (10.4±2.1 jg/liter) were no different
than those of normal dogs (10.5±3.5 psg/g and 11.9±1.2
lig/liter, respectively). After the 3 wk of aluminum administra-
tion the plasma phosphorus, parathyroid hormone, and 25-
hydroxyvitamin D concentrations were unchanged in normal
and vitamin 1-deficient dogs. Similarly, no alteration in bone
histology occurred in either group. In contrast, bone aluminum
content increased to a greater extent in the vitamin D-deficient
dogs (3903±24.3 pg/g) than in the normal dogs (73.6±10.6
jgg/g). Moreover, aluminum localized at the osteoid-bone in-
terfaces of the osteomalacic bone in the vitamin D-deficient
dogs, covering 42.9±9.2% of the osteoid-bone surface.
Further, in spite of continued aluminum chloride adminis-
tration (1 mg/kg two times per week), vitamin D repletion of
the vitamin D-deficient dogs for 11 wk resulted in normalization
of their biochemistries. In addition, while normal dogs main-
tained normal bone histology during the period of continued
aluminum administration, vitamin D repletion of the vitamin
D-deficient dogs induced healing of their bones. Indeed, the
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appearance of aluminum in the cement lines of the healed
bones indicated that mineralization had occurred at sites of
prior aluminum deposition.
These observations illustrate that aluminum deposition in
osteomalacic bone may be a secondary event that does not
influence bone mineralization. Thus, although aluminum may
cause osteomalacia in -chronic renal failure, its presence at
mineralization fronts may not be the mechanism underlying
this derangement.
Introduction
A variety of studies have implicated aluminum in the patho-
genesis of the low turnover osteomalacia that occurs in a
minority of patients with renal osteodystrophy. Epidemiological
observations have shown that a high prevalence of this bone
disease exists in patients undergoing hemodialysis with water
of high aluminum content (1-5). In addition, the severity of
the osteomalacia has been strongly correlated with the alumi-
num content of the bone (6, 7). Moreover, several investigators
have directly evaluated the potential for aluminum-induced
bone toxicity using animal model systems. In these studies
aluminum loading has been associated with the development
of defective mineralization of bone epiphyses (8) as well as
with induction of osteomalacic changes in the trabecular bone
of rats and dogs (9-1 1).
Although these observations indicate that aluminum may
cause the low turnover osteomalacia of chronic renal failure,
the mechanism by which aluminum impairs bone mineraliza-
tion remains uncertain. However, the recent observation that
aluminum is present at the nonmineralizing osteoid-bone
interfaces (calcification fronts) in bone biopsies from affected
patients (5, 12-14) suggests that aluminum localizes at the
mineralization front and directly inhibits calcification of osteoid.
Such inhibition may result from the specific effects of aluminum
or from effects dependent upon metabolic abnormalities that
are a part of the uremic state. Alternatively, the presence of
aluminum at the osteoid-bone interface may reflect deposition
in preexistent osteomalacic bone, and the aluminum may have
no direct effect on the mineralization process. Such a possibility
is consistent with the recent clinical observations that indicate
that aluminum-induced osteomalacia may be due, in part, to
a relative deficiency of parathyroid hormone (PTH)' (15, 16).
We designed the present study to determine whether
aluminum accumulates preferentially in osteomalacic bone
and, if so, whether deposition of aluminum occurs at calcifi-
cation fronts and specifically inhibits mineralization. In these
investigations we used vitamin D-deficient osteomalacic beagle
puppies as a model of osteomalacia and tested effects of
aluminum on the vitamin D-dependent mineralization process.
1. Abbreviations used in this paper: 25(OH)D, 25-hydroxyvitamin D;
PTH, parathyroid hormone.
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Study protocol. 3-mo-old beagle puppies, weighing -3 kg, were ran-
domly divided into two groups. During phase I of the study, group 1
pups (n = 5) received a normal diet containing 0.7% calcium, 0.5%
phosphorus, and 2,200 U/kg vitamin D3. In contrast, group 2 pups
(n = 5) received a matched diet that was deficient in calcium (0.4%)
and vitamin D. The group 2 animals were housed under gold fluorescent
light devoid of significant ultraviolet irradiation. After 15 wk of dietary
control we performed bone biopsies on group 1 and group 2 dogs
(aged 6.4 mo). In addition, we obtained plasma for measurement
of calcium, phosphorus, creatinine, PTH, 25-hydroxyvitamin D
(25[OH]D), and aluminum. These studies served as a baseline for
normal (group 1) and vitamin D-deficient (group 2) pups.
In phase 2 of the study animals in both groups received aluminum
chloride (1 mg/kg) intravenously three times per week for 3 wk. During
this treatment period group 1 and group 2 dogs continued receiving
normal and calcium/vitamin D-deficient diets, respectively. At the
conclusion of this phase we repeated bone biopsies and plasma
biochemistries.
During phase 3 of the study, aluminum chloride administration
was continued but both group 1 and group 2 animals received the
normal diet replete in calcium and vitamin D. All animals were housed
in quarters with ultraviolet light. During the 11 wk of phase 3 we
continued aluminum chloride administration at a reduced dose (1 mg/
kg intravenously, twice a week) to adjust the plasma aluminum
concentration (Table I) to levels more comparable to those observed
in patients with osteomalacia and chronic renal failure (12). At the
conclusion of phase 3 of the study, bone biopsies and plasma biochem-
istries were repeated in dogs, then aged 9.8 mo.
Biochemical studies. Plasma calcium and phosphorus were measured
by colorimetric techniques using an autoanalyzer (Technicon Instru-
ments Corp., Tarrytown, NY). Plasma creatinine was determined by
an enzymatic assay (17). We measured the plasma PTH concentration
using a radioimmunoassay kit (Diagnostic Systems Laboratories, Inc.,
Webster, TX) designed to measure the carboxy-terminal portion of the
molecule according to previously described methods (18). Duplicate
samples obtained from pups during each phase of the study were
measured simultaneously. The intraassay coefficient of variation for
the measurements was 10%. The plasma 25(OH)D concentration was
measured in triplicate samples by a modification of the methods of
Haddad and Chyu (19). The interassay coefficient of variation averaged
8.9%. The ionized calcium level was determined using an ICAI
analyzer (Radiometer Co., Copenhagen, Denmark), and values were
corrected to a pH of 7.4.
We assayed plasma aluminum concentration according to previously
described methods (20) using a flameless atomic absorption spectro-
photometer (Perkin-Elmer Corp., Instrument Div., Norwalk, CT) with
a graphite furnace. Interference was minimized by using a diluent
containing ammonium hydroxide. During phase 2 and 3 of the study,
when aluminum chloride was administered, the average plasma alu-
minum level was estimated by measuring the plasma concentration at
variable intervals for 48-72 h after an intravenous injection and
determining the area under the plasma concentration versus time
curve, using the trapezoidal rule, divided by the interval between
doses (21).
Bone studies. Transcortical bone biopsies were obtained from the
anterior iliac crest of dogs under general anesthesia. Chlortetracycline
(250 mg orally, twice daily) was administered to each dog over a 3-d
period from day 21 to day 18 before biopsy and demeclocycline
hydrochloride (150 mg orally, three times daily) from day 6 to day 3
before biopsy. Bone specimens were fixed in ethanol and embedded in
methylmethacrylate, unstained or prestained by the methods of Villa-
nueva (22). 20- and 5-Mim sections were made and prepared for
histomorphological examination according to previously published
methods (23). Staining for aluminum was performed on 5-Mm prestained
and unstained sections by a modification of methods reported by
Maloney et al. (13).
Histomorphometric analysis of the trabecular bone in each section
was accomplished by examining 100 fields with an integrated reticle
(Merz-Schenk, Wild, Heerbrugg, Switzerland) (24). The following
histological functions were quantitated: I) mineralization front activity,
the percentage of osteoid-covered trabecular bone surface exhibiting a
fluorescent demeclocycline hydrochloride label with a minimum width
of 3 Mm; 2) mineral apposition rate, the average distance between
chlortetracycline and demeclocycline hydrochloride fluorescent labels
divided by the days elapsed between the administration of the labels;
3) mean osteoid seam width, the mean width of 50 randomly selected
osteoid seams, each measured at four points equidistant from each
other using a linear reticle calibrated with a stage micrometer; 4)
osteoid surface, the percentage of trabecular bone surface covered by
osteoid; 5) active resorption surface, the percentage of nonosteoid-
covered trabecular bone surface on which Howship's lacunae containing
multinucleated osteoclasts are present; 6) osteoblastic surface, the
percentage of trabecular bone surface on which osteoblast-covered
osteoid is present; 7) relative osteoid volume, the percentage of
trabecular bone volume composed of unmineralized bone; 8) bone
volume, the percentage of the sample composed of trabecular bone;
and 9) aluminum surface, the percentage of osteoid-covered trabecular
bone surface bearing aluminum-stained osteoid-bone interfaces. In
Table I. Plasma Biochemistries of Group I and Group 2 Pups during Phases 1-3 ofthe Study
Alkaline
Calcium iCalcium Phosphorus PTH 25(OH)D phosphatase Aluminum
mmol/liter mmol/liter mmol/liter ng/ml ng/ml IU/liter jug/liter
Phase I
Group 1 2.70±0.03 1.41±0.01 1.98±0.03 0.49±0.03 49.0±6.6 56.6±2.8 11.9±1.2
Group 2 1.60±0.15* 0.86±0.07* 1.57±0.06* 0.88±0.05* 15.6±1.3* 164.2±5.5* 10.4±2.1
Phase 2
Group 1 2.71±0.09 1.39±0.02 1.89±0.10 0.50±0.02 51.4±7.7 70.3±11.5 4,373.2±604.9*t
Group 2 2.09±0.09*t 1.02±0.06*t 1.36±0.06* 0.86±0.07* 16.2±1.7* 137.6±10.8* 2,347.8±129.8*t
Phase 3
Group 1 2.69±0.04 1.37±0.01 2.06±0.10 0.41±0.02 70.2±15.5 46.2±7.4 1,340.6±60.6§
Group 2 2.66±0.02§ 1.36±0.01§ 2.34±0.23§ 0.42±0.05§ 83.7±20.5§ 47.1±7.1§ 1,209.7±46.1§
All values expressed as mean±SEM. * Significantly different from group 1 at P < 0.05. t Significantly different from value of comparable
group in phase I at P < 0.05. § Significantly different from values of comparable group during phase 1 and phase 2 at P < 0.05.
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addition, we calculated the following according to previously published
methods (25): 1) mineralization lag time, a measure of the time (in
days) during the life span of an osteoid moiety when mineralization is
not occurring; 2) corrected mineral apposition rate, the rate of mineral
apposition averaged throughout the life span of the osteoid seams; 3)
bone formation rate (formation surface referent), the volume of
mineralized new bone formed per unit area of osteoid surface per unit
time; and 4) bone formation rate (volume referent), the volume of
mineralized new bone made per unit volume of preexisting bone per
unit of time. Measurement of these variables in group I animals
provided normal values during phase I of the study. After aluminum
administration, however, we compared values obtained during phases
2 and 3 in group I pups with those determined in bone biopsies from
three age-matched beagle puppies maintained on a normal diet and
untreated with aluminum. Since no significant differences were observed
at 7.75 or 9.8 mo of age, we limited comparison in phases 2 and 3 of
the study to the data obtained from bone biopsies of group 1 (normal)
and group 2 pups.
We measured bone aluminum content as follows. Samples were
washed with a high pressure stream of aluminum-free water until
completely devoid of marrow. Specimens were subsequently treated in
a muffle furnace at 5500C for 12-16 h, the dry weight of each sample
was determined, and ashed specimens dissolved in 2 ml of 3% ultrapure
nitric acid. After bringing the samples to 10 ml with deionized water,
aliquots were assayed for aluminum content (20).
Statistical analyses. Results are expressed as the mean±SEM. We
performed statistical analyses of the data obtained in group 1 and 2
dogs during the three phases of study by two-way analysis of variance
and the Duncan's multiple range test (26).
Materials. The authentic 25(OH)D used in the assay for this
metabolite was a gift from Dr. Milan Uskokovic, Hoffmann-La Roche
Inc., Nutley, NJ. [3H]25(OH)D3 (90 Ci/mmol) was purchased from
Amersham Corp. (Arlington Heights, IL). Beagle puppies were obtained
from Ridglan Farms (Mount Horeb, WI) and normal and calcium/
vitamin D3-deficient diets from Teklad (Madison, WI).
Results
Phase 1. After 15 wk of a calcium and vitamin D-deficient
diet, group 2 pups displayed biochemical abnormalities char-
acteristic of vitamin D deficiency (Table I). The plasma
calcium and phosphorus concentrations of group 2 animals
were significantly less than those of group 1 normal animals.
In accord, group 2 dogs manifested an elevated plasma PTH
level. Moreover, the plasma 25(OH)D concentration of the
vitamin D-depleted pups was significantly less than that of the
normal pups. In addition, an elevated plasma alkaline phos-
phatase concentration in group 2 dogs suggested that the
vitamin D deprivation had resulted in development of osteo-
malacia.
Quantitative histomorphometric analysis of bone biopsies
confirmed the presence of osteomalacia in the vitamin D-
deprived dogs (Table II). Representative sections demonstrated
excessive osteoid surface and relative osteoid volume, changes
characteristic of the osteomalacic state. In addition, mineral-
ization dynamics were typically abnormal, resulting in a sig-
nificantly decreased mineralization front activity and mineral
apposition rate. Moreover, group 2 pups displayed a prolonged
mineralization lag time compared with group 1 animals.
Consistent with an elevated plasma PTH concentration, group
2 pups also manifested a 2.5-fold increase of active bone
resorption. However, the mineralized bone formation rate was
significantly reduced (Table II). In contrast, osteoblastic surface
of the group 2 pups was no different from that of group 1
pups (Table II).
In spite of these differences in bone histology, the bone
aluminum content was not significantly different between
groups I and 2 (Table II), and plasma aluminum levels were
indistinguishable (Table I). Histochemical staining of the bone
for aluminum revealed no evident deposition.
Phase 2. Parenteral administration of aluminum for 3 wk
resulted in no significant change in any of the measured
biochemistries in the group 1 animals (Table I). In contrast,
group 2 dogs showed a significant increase in both the plasma
ionized and total calcium concentration, while the plasma
phosphorus, PTH, 25(OH)D levels, and alkaline phosphatase
activity did not significantly deviate from values in phase 1
(Table I).
Bone histology in both groups after aluminum exposure
revealed changes consistent only with aging (Table II). Corrected
mineral apposition rate in group 1 animals decreased from
1.60±0.1 to 1.25±0.04 gm/d and bone formation rate (volume
referent) from 1.18±0.1 to 0.84±0.1 1 mm3/mm3 per yr. While
these changes represent significant declines, untreated pups of
the same age (7.25 mo) had a mineral apposition rate and
bone formation rate that are not significantly different,
1.42±0.18 ,um/d and 0.67±0.10 mm3/mm3 per yr (Table II).
In contrast, mineralization front activity, osteoid surface, mean
osteoid seam width, and relative osteoid volume were un-
changed.
In any case, administration of aluminum significantly
increased the plasma aluminum concentration and bone alu-
minum content in both group 1 and 2 dogs (Table II).
However, the bone aluminum content of group 2 osteomalacic
pups (390.3±24.3 qg/g) increased to a level greater than five
times that observed in the bones of group 1 normal pups
(73.6±10.6 ,gg/g). In accord, the plasma aluminum concentra-
tion in the osteomalacic dogs was less than that in normal
dogs (Table I). Commensurately, histological staining of the
bone biopsies from group 2 pups revealed bright red aluminum
bands covering 42.9±9.2% of the osteoid-bone interface (Table
I; Fig. 1), but there was no evidence of aluminum staining in
the bones of group 1 animals.
Phase 3. Continued administration of aluminum for an
additional 11 wk, albeit at a reduced dosage, did not alter the
plasma biochemistries or bone histology in the group 1 dogs
that remained on a normal diet (Tables I and II). In contrast,
provision of a calcium/vitamin D3-replete diet to the dogs in
group 2 and reduction of aluminum dosage resulted in normal
plasma biochemistries and healing of the osteomalacia. Plasma
calcium and phosphorus concentrations increased significantly
from the values observed in phase 1 and 2 to levels indistin-
guishable from those of group 1 dogs. Further, the plasma
PTH in group 2 dogs decreased to normal, and the plasma
25(OH)D concentration returned to a normal level that was
not significantly different from that of group 1 dogs. In
addition, the plasma alkaline phosphatase activity of group 2
dogs decreased to the normal range.
In accord, maintenance of group 2 animals on a calcium/
vitamin D3-replete diet resulted in changes in both static and
dynamic bone histomorphometric parameters indicative of
bone healing. Despite continued administration of aluminum,
albeit at a lower dosage, bone mineralization was normalized
in group 2 animals as evidenced by labeling frequencies
(mineralization front activity, 87.5±2.7%, Table II) and inter-
label distance (mineral apposition rate, 1.41±0.12 ,um/d). In
accord, mineralized bone formation rates increased to levels
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Figure 1. (top) Microscopic appearance of
bone biopsies from normal (group 1) and
vitamin D-deficient osteomalacic (group 2)
dogs after aluminum administration. (A)
Villanueva-stained specimen from a nor-
4 t> mal dog revealing little blue-stained os-
teoid. Aluminum stain did not disclose any
demonstrable aluminum at osteoid-bone
interfaces. (B) Villanueva-stained specimen
from a vitamin )-deficient (group 2) dog
after aluminum administration. Blue-
stained osteoid is abundant and covers the
majority of the trabecular bone surface. In
addition, red-stained aluminum is evident
C - over a large portion of the osteoid-bone
interface.
Figure 2. (bottom) Microscopic appearance
of a bone biopsy from a group 2 dog after
vitamin D) repletion and continued alumi-
num administration. A previously un-
stained5-. section, reacted with a histo-
chemical stain, has evident red-stained alu-
minum in a cement line. The presence of
aluminum in the cement line indicates that
mineralization had occurred at an osteoid-
bone interface where aluminum had been
previously deposited.
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significantly greater than those in group 1 dogs. The appearance
of the fluorescent bands in a discrete double linear pattern
further confirmed normal mineralization dynamics. In addition,
the mean osteoid seam width had decreased significantly into
the normal range with the consequence that mineralization
lag time had normalized. Concomitant improvements of osteoid
surface and relative osteoid volume were also observed, although
the mean values remained above those of group 1 dogs
(Table II).
The additional 11 wk of aluminum exposure further in-
creased the bone aluminum content of the group 1 dogs
(73.6±10.6 vs. 151.0±11.3 lug/g; Table II). In contrast, healing
of the osteomalacia in group 2 animals was associated with a
significant decrease of the bone aluminum content (390.3±24.3
vs. 173.5±5.6 ug/g; Table II) to a level indistinguishable from
that in group 1. Histochemical staining again revealed no
apparent aluminum in group 1 animals. Bone biopsies from
group 2 dogs that previously had identifiable aluminum at the
mineralization fronts then displayed red stained metal only in
cement lines (Fig. 2), indicating that mineralization occurred
over the previous sites of aluminum deposition.
Discussion
Considerable evidence indicates that aluminum is a pathoge-
netic factor underlying the low turnover osteomalacia in
dialysis-treated patients with chronic renal failure. The mech-
anism for the disordered bone mineralization induced by
aluminum excess, however, remains unclear. Several observa-
tions suggest that the local effects of aluminum on bone
mineralization dynamics are essential to the development of
the osteomalacia. Primary among these is the demonstration
that aluminum is concentrated at the osteoid-bone interface
(calcification front) in affected bones (5, 12-14). A consequent
disturbance of cellular and/or physiochemical processes at this
site may result in the abnormal mineralization. The association
of decreased bone aluminum content with the beneficial effects
of desferreoxamine on bone healing in affected subjects supports
this possibility (27).
However, the results of this investigation illustrate that
aluminum accumulates preferentially in preexistent osteoma-
lacic bone, localizes at the osteoid-bone interfaces, and does
not prevent mineralization. In contrast, aluminum accumula-
tion in exposed normal bones is significantly less and is not
histologically evident at the osteoid-bone interfaces. Thus, the
mere presence of aluminum at the calcification front (osteoid-
bone interface) in the osteomalacic bone does not impair
vitamin D-dependent mineralization.
In response to parenterally administered aluminum, the
bones of vitamin D-deficient osteomalacic pups accumulated
aluminum to an extent more than five times greater than that
in the bones of normal dogs (Table II). Consistent with the
enhanced accumulation, the plasma aluminum level, estimated
from pharmacokinetic data, was significantly less in the osteo-
malacic pups despite similar exposure (Table I). Further,
histological examination revealed that the aluminum in the
osteomalacic bone covered -43% of the osteoid-bone interfaces
where initial mineralization occurs. However, aluminum ad-
ministration did not affect mineralization of bone in normal
or D-deficient pups (Table II). No significant changes in
mineralization front activity, mineral apposition rate, or min-
eralization lag time occurred in group 1 or 2 pups after
administration of aluminum for 3 wk.
More important, the presence of aluminum at the osteoid-
bone interface in the bones of osteomalacic pups did not
interfere with remineralization of bones upon vitamin D
repletion. In spite of continued aluminum administration at a
reduced dosage, vitamin D therapy resulted in normalization
of mineralization and improved static parameters of bone
histology. Mineralization front activity and mineralization lag
time returned to the normal range. Indeed, the presence of
aluminum in bone cement lines (Fig. 2) indicated that the
mineralization had occurred at sites of aluminum deposition.
The similar finding of aluminum in the cement lines of bone
from humans with renal osteodystrophy is consistent with our
observations (13). In association with normal mineralization
dynamics, mean osteoid seam width was normal, while relative
osteoid volume and osteoid surface were markedly reduced
(Table II). The persistence of slightly abnormal relative osteoid
volume and osteoid surface probably represents the short
duration of treatment.
In this study, we did not observe aluminum-induced
osteomalacia in the normal dogs, results that are similar to
previous investigations (10). In contrast, several other studies
have reported that aluminum administration to rats and dogs
results in the development ofbone disease (8, 9, 1 1). In general
these disparate observations may be related to several variables.
First, the induction of osteomalacia has been associated with
using either a total dose of aluminum significantly greater than
that which we used (8, 9) or a greater amount over a shorter
period (1 1). We observed a progressive accumulation of alu-
minum in the bones of normal dogs with continuous admin-
istration in spite of reduced dosage in phase 3. However, the
plasma aluminum concentration fell by >50% during this part
of the study, potentially reducing the effects on osteoblasts.
Accordingly, abnormal bone mineralization may have resulted
from continued, or increased, aluminum administration. Sec-
ond, in most of the studies in which aluminum treatment has
induced osteomalacia, the experimental animals had impaired
renal function (9-11). Since the major (or only) route of
elimination for parenterally administered aluminum is the
kidneys, a decrease in renal function no doubt amplifies the
tissue burden for a given dose. All dogs in our study, however,
maintained normal renal function throughout the investigation.
Thus, the present studies do not preclude the possibility that
aluminum administration may cause osteomalacia if given in
higher doses or under different conditions.
In this regard the model system of osteomalacia that we
investigated has several important differences from the osteo-
malacic disease induced by aluminum in chronic renal failure.
Vitamin D deficiency in young dogs produced an osteomalacic
disorder characterized by increased osteoclast activity (Table
II). In addition, although the formation of mineralized bone
was decreased (Table II), it is possible that the enhanced PTH-
mediated resorptive activity is associated with increased for-
mation of unmineralized osteoid. We did not measure this
variable, however. In any case, the osteomalacia associated
with aluminum and chronic renal failure is adynamic and is
marked by decreased cellular activity, as well as decreased
mineralized bone formation rate and, undoubtedly, osteoid
synthesis. The increased resorption activity of vitamin D
deficiency osteomalacia, the maintenance of normal osteoblastic
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surface, and the probable enhanced rate of osteoid synthesis
may facilitate aluminum deposition and/or counteract any
effects the aluminum may have on bone mineralization. More-
over, we studied the effects of aluminum in the absence of the
metabolic complications generally associated with reduced
renal function. Such metabolic abnormalities may modulate
aluminum effects on bone mineralization.
Nevertheless, our data illustrate that aluminum deposition
in vitamin D-deficient osteomalacic bone may be a secondary
event that does not influence bone mineralization. Therefore,
although aluminum may cause osteomalacia in patients with
chronic renal failure, the presence of aluminum deposits at
the osteoid-bone interface of bones from affected patients with
a characteristic low turnover osteomalacia is insufficient to
establish the mechanism underlying the abnormal mineraliza-
tion of aluminum-induced osteomalacia. Indeed, further studies
may reveal that aluminum accumulation in body fluids and/
or organs (other than bone) causes osteomalacia by a mecha-
nism distinctly different from the postulated direct effects of
aluminum deposition on bone mineralization. In any case,
additional data are necessary to establish the mechanism by
which aluminum induces osteomalacia.
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